<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2341-4545</journal-id>
<journal-title><![CDATA[GE-Portuguese Journal of Gastroenterology]]></journal-title>
<abbrev-journal-title><![CDATA[GE Port J Gastroenterol]]></abbrev-journal-title>
<issn>2341-4545</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Gastrenterologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2341-45452022000200056</article-id>
<article-id pub-id-type="doi">10.1159/000514781</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Tofacitinib: An Option for Acute Severe Ulcerative Colitis?]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tofacitinib: uma opção na colite ulcerosa aguda grave?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gamelas]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[Guilherme]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saiote]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar de Lisboa Central  ]]></institution>
<addr-line><![CDATA[Lisbon ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>29</volume>
<numero>2</numero>
<fpage>56</fpage>
<lpage>58</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2341-45452022000200056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2341-45452022000200056&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2341-45452022000200056&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Tofacitinib has emerged as a new option for ulcerative colitis. Its rapid absorption, metabolism, and clinical improvement make it an interesting option for rescue therapy in acute severe ulcerative colitis (ASUC), a situation with limited therapeutic options in patients with a long-term disease course and multiple drug failure. The management of ASUC in this setting becomes challenging, underlying the need for new drugs and data on their efficacy and safety. We describe 2 cases of acute episodes in which tofacitinib was used as a rescue therapy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo O tofacitinib surgiu como uma nova terapêutica para a colite ulcerosa. A rapidez da sua absorção, metabolismo e melhoria clínica tornam-no uma opção apelativa como terapêutica de resgate na colite ulcerosa aguda grave (termo em inglês - ASUC), entidade esta com opções terapêuticas limitadas em doentes com longo curso de doença e falência prévia a múltiplos fármacos. A abordagem da ASUC neste contexto é desafiante, salientando-se a necessidade de novos fármacos e dados reais sobre a sua eficácia e segurança. Descrevemos dois casos de episódios agudos nos quais o tofacitinib foi utilizado como terapêutica de resgate.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Acute severe ulcerative colitis]]></kwd>
<kwd lng="en"><![CDATA[Tofacitinib]]></kwd>
<kwd lng="pt"><![CDATA[Colite ulcerosa grave]]></kwd>
<kwd lng="pt"><![CDATA[Tofacitinib]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>D'Amico F.Parigi TL.Fiorino G.Peyrin-Biroulet L.Danese S</collab>
<article-title xml:lang=""><![CDATA[Tofacitinib in the treatment of ulcerative colitis efficacy and safety from clinical trials to real-world experience]]></article-title>
<source><![CDATA[Therap Adv Gastroenterol]]></source>
<year>2019</year>
<volume>12</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bessissow]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lakatos]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2019</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2169</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Panaccione]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Danese]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cheifetz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reinisch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tofacitinib Induction Therapy Reduces Symptoms within 3 Days for Patients with Ulcerative Colitis]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>139-47</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berinstein]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Steiner]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Regal]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Kinnucan]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Stidham]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of Induction Therapy with High-Intensity Tofacitinib in 4 Patients with Acute Severe Ulcerative Colitis.]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>988-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotwani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Terdiman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lewin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis A Real-world Experience]]></article-title>
<source><![CDATA[J Crohn's Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1026-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>D'Amico F.Peyrin-Biroulet L.Danese S</collab>
<article-title xml:lang=""><![CDATA[Tofacitinib for Acute Severe Colitis When the Going Gets Tough, the Tough Get Going]]></article-title>
<source><![CDATA[J Crohn's Colitis]]></source>
<year>2020</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>883-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Honap]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pavlidis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sanderson]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tofacitinib in Acute Severe Ulcerative Colitis - A RealWorld Tertiary Center Experience]]></article-title>
<source><![CDATA[Inflamm Bowel Dis]]></source>
<year>2020</year>
<volume>26</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>e147-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
